1. Kundakci N, Erdem C. Leprosy: A great imitator. Clin Dermatol. 2019;37(3):200-12.
2. Randhawa A, Kapila R, Schwartz RA. Leprosy: what is new. Int J Dermatol. 2022;61(6):733-8.
3. Ramos-e-Siva M, Riberio de Castro MC. Mycobacterial infections. In: Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. 4th edition. 2018.
4. Virmond M, Grzybowski A, Virmond L. Leprosy: a glossary. Clin Dermatol. 2015;33(1):8-18.
5. Sarode G, Sarode S, Anand R, et al. Epidemiological aspects of leprosy. Dis Mon. 2020;66(7):100899.
6. Makhakhe L. Leprosy review. S Afr Fam Pract (2004). 2021;63(1):e1-e6.
7. Aubry A, Sammarco Rosa P, Chauffour A, Fletcher ML, Cambau E, Avanzi C. Drug resistance in leprosy: An update following 70years of chemotherapy. Infect Dis Now. 2022;52(5):243-51.
8. Schreuder PA, Noto S, Richardus JH. Epidemiologic trends of leprosy for the 21st century. Clin Dermatol. 2016;34(1):24-31.
9. mondiale de la Santé O, Organization WH. Global leprosy (Hansen disease) update, 2022: new paradigm–control to elimination–Situation de la lèpre (maladie de Hansen) dans le monde,
2022: nouveau paradigme–de la lutte contre la maladie à son l’élimination. Wkly epidemiol rec. 2023:409-29.
10. Santos VS, de Souza CDF, Martins-Filho PRS, Cuevas LE. Leprosy: why does it persist among us? Expert Rev Anti Infect Ther. 2020;18(7):613-5.
11. Leano HAM, Araújo K, Bueno IC, Niitsuma ENA, Lana FCF. Socioeconomic factors related to leprosy: an integrative literature review. Rev Bras Enferm. 2019;72(5):1405-15.
12. Sugawara-Mikami M, Tanigawa K, Kawashima A, et al. Pathogenicity and virulence of Mycobacterium leprae. Virulence. 2022;13(1):1985-2011.
13. Romero-Navarrete M, Arenas R, Han XY, Vega-Memije ME, Castillo-Solana AD. Leprosy Caused by Mycobacterium lepromatosis. Am J Clin Pathol. 2022;158(6):678-86.
14. Cardona-Castro N, Escobar-Builes MV, Serrano-Coll H, Adams LB, Lahiri R. Mycobacterium lepromatosis as Cause of Leprosy, Colombia. Emerg Infect Dis. 2022;28(5):1067-8.
15. Gilmore A, Roller J, Dyer JA. Leprosy (Hansen’s disease): An Update and Review. Mo Med. 2023;120(1):39-44.
16. Mungroo MR, Khan NA, Siddiqui R. Mycobacterium leprae: Pathogenesis, diagnosis, and treatment options. Microb Pathog. 2020;149:104475.
17. Froes LAR, Jr., Trindade MAB, Sotto MN. Immunology of leprosy. Int Rev Immunol. 2022;41(2):72-83.
18. Pinheiro RO, Schmitz V, Silva BJA, et al. Innate Immune Responses in Leprosy. Front Immunol. 2018;9:518.
19. Mi Z, Liu H, Zhang F. Advances in the Immunology and Genetics of Leprosy. Front Immunol. 2020;11:567.
20. Fava VM, Dallmann-Sauer M, Schurr E. Genetics of leprosy: today and beyond. Hum Genet. 2020;139(6-7):835-46.
21. Polycarpou A, Walker SL, Lockwood DN. New findings in the pathogenesis of leprosy and implications for the management of leprosy. Curr Opin Infect Dis. 2013;26(5):413-9.
22. Ianhez M, Cerqueira SR, Gomes CM, et al. Impact of COVID-19 on leprosy reactions and of leprosy treatments on COVID-19 severity. Indian J Dermatol Venereol Leprol. 2023;89(1):133-134.
23. Saxena S, Khurana A, B S, et al. Severe type 2 leprosy reaction with COVID-19 with a favourable outcome despite continued use of corticosteroids and methotrexate and a hypothesis on the
possible immunological consequences. Int J Infect Dis. 2021;103:549-551.
24. Gutiérrez-Villarreal IM, Ocampo-Candiani J, Villarreal-Martinez A, et al. Leprosy reactions after SARS-COV2 (COVID-19) infection. J Eur Acad Dermatol Venereol. Published online April
5, 2023.
25. Bhandari A, Shilpa, Gupta S, Dogra S, Narang T. Reactions in leprosy patients triggered by COVID-19 vaccination – a cross-sectional study from a tertiary care centre in India. J Eur Acad
Dermatol Venereol. 2022;36(12):e971-e2.
26. Alemu Belachew W, Naafs B. Position statement: LEPROSY: Diagnosis, treatment and follow-up. J Eur Acad Dermatol Venereol. 2019;33(7):1205-13.
27. Organization WH. Guidelines for the diagnosis, treatment and prevention of leprosy. 2018.
28. Maymone MBC, Laughter M, Venkatesh S, et al. Leprosy: Clinical aspects and diagnostic techniques. J Am Acad Dermatol. 2020;83(1):1-14.
29. Cruz R, Bührer-Sékula S, Penna MLF, Penna GO, Talhari S. Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all
patients. An Bras Dermatol. 2017;92(6):761-73.
30. Bala Murugan S, Mahendradas P, Dutta Majumder P, Kamath Y. Ocular leprosy: from bench to bedside. Curr Opin Ophthalmol. 2020;31(6):514-20.
31. Lockwood DNJ. Chronic aspects of leprosy-neglected but important. Trans R Soc Trop Med Hyg. 2019;113(12):813-7.
32. Tomaselli PJ, Dos Santos DF, Dos Santos ACJ, et al. Primary neural leprosy: clinical, neurophysiological and pathological presentation and progression. Brain. 2022;145(4):1499-1506.
33. Gupta SK. Histoid leprosy: review of the literature. Int J Dermatol. 2015;54(11):1283-8.
34. Khadilkar SV, Patil SB, Shetty VP. Neuropathies of leprosy. J Neurol Sci. 2021;420:117288.
35. Ebenezer GJ, Scollard DM. Treatment and Evaluation Advances in Leprosy Neuropathy. Neurotherapeutics. 2021;18(4):2337-50.
36. Bhat RM, Prakash C. Leprosy: an overview of pathophysiology. Interdiscip Perspect Infect Dis. 2012;2012:181089.
37. Turner D, McGuinness SL, Leder K. Leprosy: diagnosis and management in a developed setting. Intern Med J. 2015;45(1):109-12.
38. Malhotra KP, Husain N. Laboratory perspectives for Leprosy: Diagnostic, prognostic and predictive tools. Indian J Pathol Microbiol. 2022;65(Supplement):S300-s9.
39. Maymone MBC, Venkatesh S, Laughter M, et al. Leprosy: Treatment and management of complications. J Am Acad Dermatol. 2020;83(1):17-30.
40. Smith CS, Aerts A, Saunderson P, Kawuma J, Kita E, Virmond M. Multidrug therapy for leprosy: a game changer on the path to elimination. Lancet Infect Dis. 2017;17(9):e293-e7.
41. Kar HK, Gupta R. Treatment of leprosy. Clin Dermatol. 2015;33(1):55-65.
42. Richardus JH, Oskam L. Protecting people against leprosy: chemoprophylaxis and immunoprophylaxis. Clin Dermatol. 2015;33(1):19-25.
43. Schoenmakers A, Mieras L, Budiawan T, van Brakel WH. The State of Affairs in Post-Exposure Leprosy Prevention: A Descriptive Meta-Analysis on Immuno- and Chemo-Prophylaxis. Res
Rep Trop Med. 2020;11:97-117.
44. Steinmann P, Reed SG, Mirza F, Hollingsworth TD, Richardus JH. Innovative tools and approaches to end the transmission of Mycobacterium leprae. Lancet Infect Dis. 2017;17(9):e298-e305.